Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: The IMPACT-ALS survey collected the experiences of people living with ALS (plwALS) across nine European countries. We aimed to better understand the functional burden of ALS to ensure the experiences of plwALS inform the development of person-centered therapies.

Methods: The content was informed by the US IMPACT-ALS survey, with adjustments relevant to the European population. Questionnaires consisted of four modules, each of which was pilot tested in advance of distribution. Data were captured using the Qualtrics software and were analyzed in SPSS.

Results: 857 respondents completed the survey, with a participation rate ranging from 0.2% to 6.3% across the nine participating countries. The majority were male and aged 55-74 years old. In the previous 2 weeks, symptoms experienced included weakness (81%), fatigue (61%), speech impairment (38%), pain (27%), and depression and other mood changes (23%). Eighty-two percent of respondents reported fears, of which the most common were leaving family too soon (68%) and death from respiratory failure (50%). Lifestyle changes since diagnosis were reported by 89% of respondents, with less time spent doing most daily activities but more time on the internet (81%), reading (56%) and communicating with family and friends (55%). Stopping progression of ALS was the most desired impact for a new therapy for 68% respondents.

Conclusions: The European IMPACT-ALS survey has generated insights into the complex experiences of plwALS. The data provide unique patient perspectives on common symptoms, fears, functional limitations, lifestyle changes, and wishes for future therapies that will enhance patient-centric care in ALS.

Download full-text PDF

Source
http://dx.doi.org/10.1080/21678421.2023.2249515DOI Listing

Publication Analysis

Top Keywords

impact-als survey
12
people living
8
living als
8
experiences plwals
8
lifestyle changes
8
survey
5
als
5
impact-als
4
impact-als summary
4
european
4

Similar Publications

Background: Amyotrophic lateral sclerosis (ALS) is a highly debilitating neurodegenerative condition. Despite recent advancements in understanding the molecular mechanisms underlying ALS, there have been no significant improvements in therapeutic options for ALS patients in recent years. Currently, there is no cure for ALS, and the only approved treatment in Europe is riluzole, which has been shown to slow the disease progression and prolong survival by approximately 3 months.

View Article and Find Full Text PDF

IMPACT-ALS: summary of results from a European survey of people living with ALS.

Amyotroph Lateral Scler Frontotemporal Degener

September 2023

Academic Unit of Neurology, Clinical Medicine, Trinity College Dublin, Dublin, Ireland.

Article Synopsis
  • The IMPACT-ALS survey aimed to gather the experiences of people living with ALS across nine European countries to inform the development of person-centered therapies.
  • A total of 857 participants completed the survey, revealing common symptoms like weakness and fatigue, along with significant fears related to their condition.
  • The survey highlighted that nearly all respondents reported lifestyle changes post-diagnosis, notably spending more time online and wanting therapies focused on halting ALS progression.
View Article and Find Full Text PDF
Article Synopsis
  • Primary lateral sclerosis (PLS) is a condition where important brain cells, called upper motor neurons, gradually stop working properly, mostly affecting movement.
  • This study looked at how the brain and muscles communicate during a hand task in people with PLS compared to healthy individuals, using special tools to measure brain activity (EEG) and muscle activity (EMG).
  • The results showed unusual patterns of brain and muscle interaction in PLS patients, suggesting that their brains might be trying to adapt to the disease, which could help understand how PLS affects movement.
View Article and Find Full Text PDF

Background: Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative rare disease that affects motor neurons in the brain, brainstem, and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal muscles. Although much has been achieved in understanding the disease pathogenesis, treatment options are limited, and in Europe, riluzole is the only approved drug. Recently, some other drugs showed minor effects.

View Article and Find Full Text PDF

Nutrition concerns are prevalent in individuals with Amyotrophic Lateral Sclerosis (ALS). Despite the prevalence of nutrition concerns, few data are available on perceptions and experiences of nutrition interventions in individuals with ALS and their caregivers; this study aimed to collect this information. An online survey was developed and hosted on Survey Monkey.

View Article and Find Full Text PDF